Table 2.

HR with 95% CI of DFS and of OS by clinicopathologic parameters of patients with EOC who received six courses of adjuvant platinum-based chemotherapy (n = 30), using univariate Cox Regression

	n	DFS	(95% CI)	P	OS	(95% CI)	P
	n	HR	(95% CI)	P	HR	(95% CI)	P
GSTP1-1
Low (≤160 ng/mL)	12	1.00	(Reference)		1.00	(Reference)
High (>160 ng/mL)	18	2.79	(0.97-8.04)	0.058^*	4.50	(0.97-20.92)	0.055^*
FIGO stage
I + II	11	1.00	(Reference)		1.00	(Reference)
III + IV	19	10.17	(2.25-45.99)	0.003^*	3.12	(0.84-11.59)	0.089^*
Residual disease
<1 cm	18	1.00	(Reference)		1.00	(Reference)
≥1 cm	12	1.56	(0.52-4.67)	0.424	1.06	(0.28-4.03)	0.935
Malignant cells in ascites
No	9	1.00	(Reference)		1.00	(Reference)
Yes	20	5.07	(1.14-22.65)	0.033^*	2.30	(0.61-8.67)	0.218
Preoperative CA 125
≤126 U/mL	11	1.00	(Reference)		1.00	(Reference)
>126 U/mL	18	2.65	(0.82-8.60)	0.104	4.97	(1.06-23.20)	0.041^*

↵*Parameters with a P value of ≤0.10 were selected for multivariate analysis.